

2016 – The Year to Focus Real-World Evidence on Pricing and Reimbursement

EVIDERA'S PRICING AND REIMBURSEMENT POLICY COUNCIL (PRPC) provided feedback in September 2015 on key topics. A short synopsis is highlighted below.

(Membership of the PRPC include: National Payers and Advisers to Pricing and Reimbursement Committees in England, Germany, France, Italy and Spain – one member per market.)

1. Indications of importance for Real-World Evidence Generation to inform pricing and reimbursement of new molecules

	1st	2nd	3rd
Italy	Orphan indications	Cancer and Autoimmune Conditions (Rheumatoid Arthritis [RA], Crohn's Disease, Psoriasis)	Cancer and Autoimmune conditions (RA, Crohn's Disease, Psoriasis)
Spain	Cancer	Diabetes, Dyslipidaemia	Autoimmune Conditions (RA, Crohn's Disease, Psoriasis)
Germany	Diabetes	Dyslipidaemia	Dementia
France	Diabetes	Autoimmune Conditions (RA, Crohn's Disease, Psoriasis)	Selected Cancers
England	Cancer	Cardiology	Respiratory

2. Should the evidence be provided pre-launch or post-launch?

	1st	2nd	3rd
Italy	Orphan indications	Cancer and Autoimmune Conditions (RA, Crohn's, Psoriasis)	Cancer and Autoimmune Conditions (RA, Crohn's, Psoriasis)
Spain	Cancer	Diabetes, Dyslipidaemia	Autoimmune Conditions (RA, Crohn's, Psoriasis)
Germany	Diabetes	Dyslipidaemia	Dementia
France	Diabetes	Autoimmune Conditions (RA, Crohn's, Psoriasis)	Selected Cancers
England	Cancer	Cardiology	Respiratory

Green: Pre-launch Blue: Post-launch

3. For market access decision-making in your country, will price increase in importance compared to all other pricing and reimbursement requirements?

	Answer	Verbatim Comments
Italy	Yes	'Pricing per indication may represent a possible evolution'
Spain	No	'Health economics is more meaningful than price!'
Germany	Yes	'Health economics is not an issue for us – but obviously price is!'
France	No	'For us, the next step will be to complement economic evaluation (efficiency) with budget impact models (affordability). That is, something more complex than simple price.'
England	Yes	'To some extent, affordability will bite harder! [There is] potential for more competitive tendering to drive price down in areas where several products have [the] same efficacy.'

For more information, please contact Susanne.Michel@evidera.com.